A phase II study combining bendamustine and obinutuzumab showed promising results in patients with previously untreated chronic lymphocytic leukemia (CLL). Dr. Jeff Sharman, the director of research at WVCI and the medical director of hematology research for The US Oncology Network, discussed the results of the GIBB trial at the 2017 American Society of Hematology conference.

“There remains a population of patients for whom chemoimmunotherapy might be a desirable first-line therapy,” Dr. Sharman said in an interview for the publication Targeted Oncology. “In my mind, the stratification between a tyrosine kinase inhibitor versus chemotherapy falls along the IGHV mutation status. If you are mutated, you are going to have a more favorable response to chemotherapy. If you are going to give chemotherapy, this may be a suitable option for such a patient.”